{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:24:02Z","timestamp":1782440642468,"version":"3.54.5"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>The aim of this study was to assess the association among toxicity, dosimetry of organs-at-risk, and disease progression in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with <jats:sup>177<\/jats:sup>Lu-DOTATATE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Thirty-seven patients with GEP-NETs underwent <jats:sup>177<\/jats:sup>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in a single-arm, prospective, phase 2 study, where patients were followed up with blood tests, isotopic glomerular filtration rate (iGFR), and imaging examinations (CT\/MRI and PET) every 6 months until disease progression. Adverse events (AEs) graded per CTCAEv4.03 and occurring during treatment were collected and followed up until resolution. Dosimetry, including biologically effective doses (BEDs) to kidneys, BED to bone marrow, and absorbed dose (AD) to spleen, was performed after each PRRT cycle. Statistical analyses explored associations among dosimetry, toxicity, and patient progression free-survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The most common AEs were anemia and lymphopenia (65%), followed by thrombocytopenia and fatigue (each 51%), alopecia (46%), and nausea (41%). The most common grade \u22653 AE was lymphopenia (43%). There was no grade \u22653 nephrotoxicity. The median iGFR % decrease was 11% (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), at a median follow-up of 23 months. iGFR %decrease and renal BED did not correlate (Spearman \u03c1 = \u22120.09). Similarly, no significant association was found between bone marrow BED or spleen AD and the grades of hematological toxicities. We observed no association between progression free-survival and either the decline of renal function or the occurrence of hematological toxicities during PRRT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study confirms the safety profile of <jats:sup>177<\/jats:sup>Lu-DOTATATE PRRT in patients with GEP-NETs irrespective of the dosimetry of organs at risk. Kidney, bone marrow, and spleen dosimetry measures were not associated with renal or hematological toxicity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005330","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T22:00:10Z","timestamp":1719266410000},"page":"847-853","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors"],"prefix":"10.1097","volume":"49","author":[{"given":"Magdalena","family":"Mileva","sequence":"first","affiliation":[{"name":"Nuclear Medicine Department, Institut Jules Bordet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Van Bogaert","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, CUB H\u00f4pital Erasme"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenna\u00eblle","family":"Marin","sequence":"additional","affiliation":[{"name":"Medical Physics Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Danieli","sequence":"additional","affiliation":[{"name":"Medical Physics Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Artigas","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Institut Jules Bordet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Levillain","sequence":"additional","affiliation":[{"name":"Medical Physics Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieveke","family":"Ameye","sequence":"additional","affiliation":[{"name":"Data Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loubna","family":"Taraji-Schiltz","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Institut Jules Bordet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Stathopoulos","sequence":"additional","affiliation":[{"name":"Radiology Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z\u00e9na","family":"Wimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Hendlisz","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Institut Jules Bordet, ENETS Centre of Excellence, H\u00f4pital Universitaire de Bruxelles, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Flamen","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Institut Jules Bordet"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Karfis","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Institut Jules Bordet"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","year":"2008","journal-title":"J Clin Oncol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","article-title":"Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors","volume":"35","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1007\/s00259-019-04389-2","article-title":"Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide\/chemoradionuclide therapy (PRRT\/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00259-020-05127-9","article-title":"Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1530\/ERC-16-0258","article-title":"Myeloid neoplasms after chemotherapy and PRRT: myth and reality","volume":"23","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40658-016-0153-4","article-title":"Radiation exposure of the spleen during 177Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume","volume":"3","year":"2016","journal-title":"EJNMMI Phys"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","article-title":"Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib10-20250621","first-page":"593","article-title":"Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"27","year":"2012","journal-title":"Cancer Biother Radiopharm"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","article-title":"Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s00259-017-3688-2","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","year":"2017","journal-title":"Clin Cancer Res"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejmp.2018.11.001","article-title":"A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours","volume":"56","year":"2018","journal-title":"Phys Med"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/01.mnm.0000136715.71820.4a","article-title":"Guidelines for the measurement of glomerular filtration rate using plasma sampling","volume":"25","year":"2004","journal-title":"Nucl Med Commun"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","article-title":"Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate","volume":"36","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/00004032-200309000-00006","article-title":"Physical models and dose factors for use in internal dose assessment","volume":"85","year":"2003","journal-title":"Health Phys"},{"key":"bib18-20250621","first-page":"363","article-title":"Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy","volume":"19","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/09553008814551461","article-title":"Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction?","volume":"54","year":"1988","journal-title":"Int J Radiat Biol"},{"key":"bib20-20250621","first-page":"263","article-title":"Tissue repair capacity and repair kinetics deduced from multifractionated or continuous irradiation regimens with incomplete repair","volume":"6","year":"1984","journal-title":"Br J Cancer Suppl"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","year":"2009","journal-title":"Blood"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s00259-016-3382-9","article-title":"Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"bib23-20250621","first-page":"83S","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA(0),Tyr(3)-octreotide and 177Lu-DOTA(0), Tyr(3)-octreotate","volume":"46","year":"2005","journal-title":"J Nucl Med"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2967\/jnumed.121.263056","article-title":"Safety of peptide receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumor patients with chronic kidney disease","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00259-003-1117-1","article-title":"86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)\u2014a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion","volume":"30","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib28-20250621","first-page":"565","article-title":"Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets","volume":"150","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1006\/cimm.1997.1193","article-title":"Expression of somatostatin receptor subtype 2 mRNA in human lymphoid cells","volume":"181","year":"1997","journal-title":"Cell Immunol"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2967\/jnumed.114.145581","article-title":"Analysis of 177Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors","volume":"56","year":"2015","journal-title":"J Nucl Med"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"1201500","DOI":"10.3389\/fonc.2023.1201500","article-title":"A review on lymphocyte radiosensitivity and its impact on radiotherapy","volume":"13","year":"2023","journal-title":"Front Oncol"},{"key":"bib32-20250621","first-page":"659","article-title":"Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC","volume":"24","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"eabb3631","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","year":"2021","journal-title":"Sci Transl Med"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"e000980","DOI":"10.1136\/jitc-2020-000980","article-title":"Phase I study of the 177Lu-DOTA(0)-Tyr(3)-Octreotate (Lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung","volume":"8","year":"2020","journal-title":"J Immunother Cancer"},{"key":"bib36-20250621","first-page":"C25","article-title":"A pilot study of pembrolizumab and peptide receptor radionuclide therapy for patients with metastatic well-differentiated neuroendocrine tumors","volume":"98","year":"2023","journal-title":"Endocrine Abstracts"},{"key":"bib37-20250621","first-page":"134","article-title":"Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy","volume":"48","year":"2007","journal-title":"J Nucl Med"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00259-015-3193-4","article-title":"Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","article-title":"Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"54","year":"2013","journal-title":"J Nucl Med"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.2967\/jnumed.123.265484","article-title":"Specific uptake in the bone marrow causes high absorbed red marrow doses during 177Lu-DOTATATE treatment","volume":"64","year":"2023","journal-title":"J Nucl Med"},{"key":"bib41-20250621","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2967\/jnumed.118.225235","article-title":"Bone marrow absorbed doses and correlations with hematologic response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases","volume":"60","year":"2019","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:03:43Z","timestamp":1750532623000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005330"}},"subtitle":["Data From the Prospective Phase 2 LUMEN Study"],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005330","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,19]]}}}